MannKind Corporation (MNKD) P/E Ratio History
ExpensiveTrading at 197.0x vs 5Y avg 84.6x · 91th percentile · Material premium to history · Data 2016–2025
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, MannKind Corporation (MNKD) trades at a price-to-earnings ratio of 197.0x, with a stock price of $3.94 and trailing twelve-month earnings per share of $-0.08.
The current P/E is 133% above its 5-year average of 84.6x. Over the past five years, MNKD's P/E has ranged from a low of 1.0x to a high of 287.8x, placing the current valuation at the 91th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, MNKD trades at a 791% premium to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, MNKD commands a significant premium over the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MNKD DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MNKD Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
MNKD P/E vs Peers
Metabolic and Obesity Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $23B | 19.3 | 1.00 | +13% | |
| $4B | 9.4Lowest | - | +68% | |
| $7B | 10.2 | - | +264%Best | |
| $192B | 12.2 | 0.59 | +2% | |
| $102B | 18.2 | - | -7% | |
| $1.0T | 47.8 | 1.66 | +96% | |
| $28B | 34.7 | 3.31 | +47% | |
| $10B | 41.9 | 0.41Best | -40% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
MNKD Historical P/E Data (2016–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $5.67 | $0.02 | 287.8x | +240% |
| FY2025 Q3 | - | $5.37 | $0.09 | 57.0x | -33% |
| FY2025 Q2 | Jun 30 2025 | $3.74 | $0.11 | 34.2x | -60% |
| FY2025 Q1 | Mar 31 2025 | $5.03 | $0.10 | 50.5x | -40% |
| FY2024 Q4 | - | $6.43 | $0.09 | 70.4x | -17% |
| FY2024 Q3 | Sep 30 2024 | $6.29 | $0.07 | 89.6x | +6% |
| FY2024 Q2 | Jun 30 2024 | $5.22 | $0.04 | 145.0x | +71% |
| FY2024 Q1 | Mar 31 2024 | $4.53 | $0.02 | 191.9x | +127% |
| FY2017 Q2 | Jun 30 2017 | $1.41 | $1.35 | 1.0x | -99% |
| FY2017 Q1 | Mar 31 2017 | $1.48 | $1.37 | 1.1x | -99% |
| FY2016 Q4 | Dec 31 2016 | $3.18 | $1.25 | 2.5x | -97% |
Average P/E for displayed period: 84.6x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MNKD — Frequently Asked Questions
Quick answers to the most common questions about buying MNKD stock.
What is MNKD's P/E ratio?
MannKind Corporation (MNKD) trailing twelve-month P/E ratio is 197.0x, based on TTM diluted EPS of $-0.08. The 5-year average P/E is 84.6x and the historical range spans 1.0x to 287.8x.
Is MNKD stock overvalued or undervalued?
MNKD trades at 197.0x P/E, above its 5-year average of 84.6x. The 91th percentile ranking within the 1.0x–287.8x historical range indicates a premium to historical valuation.
Is MNKD stock expensive?
Yes, MNKD is expensive relative to its own history. The current P/E of 197.0x is above the 5-year average of 84.6x and also above the Healthcare sector median of 22.1x. The stock sits at the 91th percentile of its 5-year valuation range.
What is MNKD's historical P/E range?
Over the past 5 years, MNKD's P/E ratio has ranged from 1.0x to 287.8x, with a median of 57.0x and an average of 84.6x. The current P/E of 197.0x places the stock at the 91th percentile of this range. Full historical data spans 2016–2025.
How does MNKD's P/E compare to the S&P 500?
MNKD trades at 197.0x P/E versus the S&P 500 median of 24.4x. The 707% premium to the market typically reflects higher expected earnings growth or quality.
How does MNKD's valuation compare to Healthcare peers?
MannKind Corporation P/E of 197.0x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is MNKD's PEG ratio?
MNKD PEG ratio is N/A, based on a P/E of 197.0x and EPS growth of -79.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is MNKD's earnings yield?
MNKD earnings yield is 0.51%, the inverse of its 197.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.